qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:2ff0a713ccb84a1d6eecb8f3 | QAG:a043bbcf955e6eedd0a4a680 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Methods Patients with HER2‐overexpressing (IHC 2+ or 3+), locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second‐line therapy were eligible and received RC48 2.5 mg/kg alone every 2 weeks"? Return the original wording ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:32fd278c95b64d239d4e1a49","quotes":["Methods Patients with HER2‐overexpressing (IHC 2+ or 3+), locally advanced o... | [
"CLM:32fd278c95b64d239d4e1a49",
"CLM:07188d589c90a9f6b66a8e97"
] | [
"PMCID:PMC8626607"
] | [
"SPAN:5cc6bdded75a34203edee1cb"
] | [] | [] | {"qa_id":"QA:2ff0a713ccb84a1d6eecb8f3","qa_group_id":"QAG:a043bbcf955e6eedd0a4a680","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Methods Patients with HER2‐overexpressing (IHC 2+ or 3+), locally ... |
QA:31036dd797247a76e8cb64ed | QAG:b7be1c3a294e0989306f0d69 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "4 months for patients who received chemotherapy, and no survival benefit despite a proportion of these patients sequenced onto second- or third-line treatment"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirem... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b8f98aa274d0db4a875f37e9","quotes":["Similarly, in the first-line setting, over 60% of patients with PD-L1-positi... | [
"CLM:b8f98aa274d0db4a875f37e9",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC7602637"
] | [
"SPAN:0ab3c196ce00c5481ec81caa"
] | [] | [] | {"qa_id":"QA:31036dd797247a76e8cb64ed","qa_group_id":"QAG:b7be1c3a294e0989306f0d69","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"4 months for patients who received chemotherapy, and no survival b... |
QA:3d2b804cf762914ab42ce9a1 | QAG:86759d0cb369c95819174094 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "The lack of a formal, nationwide, gastric cancer screening program has led to a lower early detection rate in China compared with those in other Asian countries; the 5-year overall survival (OS) rate for Chinese patients with gastric cancer has been reported to be 54.3... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3dd0f0d29cb356f9a00a37ce","quotes":["The lack of a formal, nationwide, gastric cancer screening program has contr... | [
"CLM:3dd0f0d29cb356f9a00a37ce",
"CLM:32fd278c95b64d239d4e1a49"
] | [
"PMCID:PMC6591878"
] | [
"SPAN:f95b2b310ac83fec9b6d7211"
] | [] | [] | {"qa_id":"QA:3d2b804cf762914ab42ce9a1","qa_group_id":"QAG:86759d0cb369c95819174094","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"The lack of a formal, nationwide, gastric cancer screening program... |
QA:3e6982d4e0faf766361714fa | QAG:1a248fb26474cc932f30dec4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Here we report the results from the JVDF phase 1a/b trial, where a first-line advanced/metastatic G/GEJ adenocarcinoma cohort of 28 patients received ramucirumab and pembrolizumab"? Return the original wording with paper, Claim, and Evidence Span references.
Integrate... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ddcc1b1ed281f24088c7e6a2","quotes":["Here we report the results from the JVDF phase 1a/b trial, where a first-lin... | [
"CLM:ddcc1b1ed281f24088c7e6a2",
"CLM:3dd0f0d29cb356f9a00a37ce"
] | [
"PMCID:PMC7602637"
] | [
"SPAN:d55b4530cf13fd11da8d9613"
] | [] | [] | {"qa_id":"QA:3e6982d4e0faf766361714fa","qa_group_id":"QAG:1a248fb26474cc932f30dec4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Here we report the results from the JVDF phase 1a/b trial, where a... |
QA:4157276b7eefd90713d6382f | QAG:39374a8fe930edaf5de4654f | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Pembrolizumab combined with chemotherapy in the treatment of advanced, unresectable, and metastatic EAC/GEA led to longer PFS (HR = 0.63 [98% CI 0.46–0.87]; p = 0.004) than chemotherapy alone in KEYNOTE-590. In a study from Asia, ATTRACTION-4, nivolumab plus chemothera... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:266e6db0a42e073cd5cbc5df","quotes":["Subgroup analysis also dem... | [
"CLM:266e6db0a42e073cd5cbc5df",
"CLM:07188d589c90a9f6b66a8e97",
"CLM:8c6758936c08b72928d88b5a",
"CLM:6ee7ab0c2b485e3cec13aff8"
] | [
"PMCID:PMC10129365",
"PMID:32208960",
"PMCID:PMC7602637"
] | [
"SPAN:75a52ef22cc7e2ba800cab07",
"SPAN:bd2f2273651bca1b6e49d7b6",
"SPAN:0ab3c196ce00c5481ec81caa"
] | [
"ASC2:efd13dd1b6afd7d0e79ba440",
"ASC2:29279dc2ad6852c9c959e9bd"
] | [
"HYP:DCH:034a2cac8fa0c57da717f1f2",
"HYP:DCH:6ac9140787b9ffaf85eb7112"
] | {"qa_id":"QA:4157276b7eefd90713d6382f","qa_group_id":"QAG:39374a8fe930edaf5de4654f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Pembrolizumab combined with chemotherapy in the treatment of advan... |
QA:4330bfed19c8b683063e459e | QAG:e1117684d087fd60e6d3709e | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8266790? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8266790","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8266790"
] | [] | [] | [] | {"qa_id":"QA:4330bfed19c8b683063e459e","qa_group_id":"QAG:e1117684d087fd60e6d3709e","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8266790... |
QA:43547ea858607aa32c78fe4a | QAG:90f41e525bc6b4f05e19f655 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Although several clinical trials have investigated the efficacy of molecular agents for G/GEJ cancer, only trastuzumab and ramucirumab achieved favorable survival times"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenanc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:07188d589c90a9f6b66a8e97","quotes":["Although several clinical trials have investigated ... | [
"CLM:07188d589c90a9f6b66a8e97",
"CLM:266e6db0a42e073cd5cbc5df",
"CLM:619cf140fcdd7c535b17a748"
] | [
"PMCID:PMC6386029",
"PMCID:PMC7781732"
] | [
"SPAN:413f601150ed9386bc71b8ec",
"SPAN:4ae33b94f6a1c28552744dd4"
] | [
"ASC2:286c6e807bec7aa05b904164"
] | [
"HYP:DCH:14c4d1630341554e285ed314"
] | {"qa_id":"QA:43547ea858607aa32c78fe4a","qa_group_id":"QAG:90f41e525bc6b4f05e19f655","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Although several clinical trials have investigated the efficacy of... |
QA:43bb0ada738ba79ee16200cb | QAG:f23bb9692346790ba768a74a | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7007286? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC7007286","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC7007286"
] | [] | [] | [] | {"qa_id":"QA:43bb0ada738ba79ee16200cb","qa_group_id":"QAG:f23bb9692346790ba768a74a","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7007286... |
QA:46a29f1d74f45af42aeff2da | QAG:7b2bf9da3a6e4d12c1fb63e7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "The results of this long-term follow-up of ATTRACTION-2 demonstrated that compared with placebo, nivolumab prolonged the OS (5.26 vs 4.14 months), with numerically higher OS (10.6% vs 3.2%) and PFS rates (3.8% vs 0%) at 2 years in patients with unresectable advanced or... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cd5f814c042e48305418beff","quotes":["The results of this long-term follow-up of ATTRACTI... | [
"CLM:cd5f814c042e48305418beff",
"CLM:3add2a9d54141ff5edee4d18",
"CLM:dec01f52791478c4dca2ca20"
] | [
"PMCID:PMC7165140",
"PMCID:PMC6386029"
] | [
"SPAN:1cc8d921244bda8790343af5",
"SPAN:62615bc84d2795a1ffbcc4bb"
] | [
"ASC2:bb0315df8b649620021249fe"
] | [
"HYP:DCH:e2df982815e1f162c2c53ba9"
] | {"qa_id":"QA:46a29f1d74f45af42aeff2da","qa_group_id":"QAG:7b2bf9da3a6e4d12c1fb63e7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"The results of this long-term follow-up of ATTRACTION-2 demonstrat... |
QA:46abb9501d73db91c86494da | QAG:bca1fcaceb11f573640cb3e2 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:33504550? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:33504550","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:33504550"
] | [] | [] | [] | {"qa_id":"QA:46abb9501d73db91c86494da","qa_group_id":"QAG:bca1fcaceb11f573640cb3e2","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:33504550? E... |
QA:46ae1d92fc4a7aa7038fd7cf | QAG:6677bbbffbc798df4b4fc735 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10166915? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10166915","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10166915"
] | [] | [] | [] | {"qa_id":"QA:46ae1d92fc4a7aa7038fd7cf","qa_group_id":"QAG:6677bbbffbc798df4b4fc735","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1016691... |
QA:470ab351ae34b2a4ce321463 | QAG:3f277589fb1d6dad93e53232 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Similarly, in the first-line setting, over 60% of patients with PD-L1-positive G/GEJ cancer who received pembrolizumab monotherapy progressed rapidly, with a median PFS of 2.0 months compared with 6.4 months for patients who received chemotherapy, and no survival benef... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6ee7ab0c2b485e3cec13aff8","quotes":["Similarly, in the first-line setting, over 60% of p... | [
"CLM:6ee7ab0c2b485e3cec13aff8",
"CLM:3add2a9d54141ff5edee4d18",
"CLM:072282e1a03a6f258ddcaf17",
"CLM:685d093fc973a58e3e19dad5",
"CLM:b1e271353e1dceabac1155f3"
] | [
"PMCID:PMC7602637",
"PMCID:PMC8397221",
"PMCID:PMC6882659"
] | [
"SPAN:0ab3c196ce00c5481ec81caa",
"SPAN:b090b5b651896cb19b6ff8b3",
"SPAN:bafcbacb51e76a433e87a5c0",
"SPAN:d352cd023c16005c02046b8f"
] | [
"ASC2:3bd33acc30cde3d844aa36e3",
"ASC2:5cbb1a1c35e265b6385dd695"
] | [
"HYP:DCH:8a1090ec4b40b824282569b8"
] | {"qa_id":"QA:470ab351ae34b2a4ce321463","qa_group_id":"QAG:3f277589fb1d6dad93e53232","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Similarly, in the first-line setting, over 60% of patients with PD... |
QA:4a74dc727cfcdbc8846d7904 | QAG:429157f3a6321ff3a0698a4d | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7667450? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC7667450","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC7667450"
] | [] | [] | [] | {"qa_id":"QA:4a74dc727cfcdbc8846d7904","qa_group_id":"QAG:429157f3a6321ff3a0698a4d","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7667450... |
QA:4e5781727b3176e8e57505d0 | QAG:e7f787cf6c62e2ed5ae4cadc | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Results Four RCTs with a total of 3,013 patients researching the efficacy of immunotherapy plus chemotherapy versus chemotherapy alone on gastrointestinal cancer were included in this meta-analysis"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6bf05ebcab646cbcedadb313","quotes":["Results Four RCTs with a total of 3,013 patients researching the efficacy of... | [
"CLM:6bf05ebcab646cbcedadb313",
"CLM:072282e1a03a6f258ddcaf17"
] | [
"PMCID:PMC10129365"
] | [
"SPAN:87e5d59e1c010c04aa9cec4b"
] | [] | [] | {"qa_id":"QA:4e5781727b3176e8e57505d0","qa_group_id":"QAG:e7f787cf6c62e2ed5ae4cadc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Results Four RCTs with a total of 3,013 patients researching the e... |
QA:50a0f20676f93080d9a4325a | QAG:4a7a1a4a736cd5d344a44c9d | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "In the phase I/II CheckMate 032 study in patients with chemotherapy-refractory G/GEJ/esophageal cancer, nivolumab monotherapy led to an ORR of 12%, median OS of 6.2 months, and 12-month OS rate of 39%"? Return the original wording with paper, Claim, and Evidence Span r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:912934723bc226cd027688fb","quotes":["In the phase I/II CheckMate 032 study in patients with chemotherapy-refracto... | [
"CLM:912934723bc226cd027688fb",
"CLM:32fd278c95b64d239d4e1a49"
] | [
"PMCID:PMC6386029"
] | [
"SPAN:23dd7deea2698a2b1cd7470a"
] | [] | [] | {"qa_id":"QA:50a0f20676f93080d9a4325a","qa_group_id":"QAG:4a7a1a4a736cd5d344a44c9d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"In the phase I/II CheckMate 032 study in patients with chemotherap... |
QA:512a262e0fe9b70c2cba8327 | QAG:fa9a5114f035b1193d9662e1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "All patients received treatment in the Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:33c18465cb94d01ee8f726c0","quotes":["A single-arm, open-label, phase 2 trial ( NCT048903... | [
"CLM:33c18465cb94d01ee8f726c0",
"CLM:3add2a9d54141ff5edee4d18",
"CLM:072282e1a03a6f258ddcaf17"
] | [
"PMCID:PMC9491115",
"PMCID:PMC8397221"
] | [
"SPAN:cec9b3046036a6bf3cd9d4f1",
"SPAN:b090b5b651896cb19b6ff8b3"
] | [
"ASC2:043e0f9bf3036ec5f4244405"
] | [] | {"qa_id":"QA:512a262e0fe9b70c2cba8327","qa_group_id":"QAG:fa9a5114f035b1193d9662e1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"All patients received treatment in the Department of Gastrointesti... |
QA:5282c5f9a7d8c27501b5b710 | QAG:b051a4aac3d4462676656f2b | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8923733? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8923733","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8923733"
] | [] | [] | [] | {"qa_id":"QA:5282c5f9a7d8c27501b5b710","qa_group_id":"QAG:b051a4aac3d4462676656f2b","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8923733... |
QA:5366b0e4eb04de43aa00dc07 | QAG:eaa3ca06613424600fc5a009 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Moreover, in a phase 3 trial (JACOB), metastatic G/GEJ cancer patients received pertuzumab (another anti-HER2 antibody) or placebo in combination with trastuzumab plus chemotherapy (standard cisplatin/fluoropyrimidine regimen) as first-line treatment; OS was not signif... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d19095ebc6f8938df81a5bd3","quotes":["Moreover, in a phase 3 tri... | [
"CLM:d19095ebc6f8938df81a5bd3",
"CLM:6e9c0ee57fac704864253bf1",
"CLM:3add2a9d54141ff5edee4d18",
"CLM:43cde8df325291a4af2574ba"
] | [
"PMCID:PMC6942596",
"PMCID:PMC10679498",
"PMCID:PMC9813086"
] | [
"SPAN:7a5cdc80a8e4d53efb1638c4",
"SPAN:ab8a8d2763f48c350ba97a29",
"SPAN:a0c8a381518c85cb2105251c"
] | [
"ASC2:608428d411578ac67ac32266",
"ASC2:32404a451e3dd9d9443791e1"
] | [
"HYP:DCH:6814527b6c482d06fb1bd8f2",
"HYP:DCH:0120722ce2f93e34e006cdd6"
] | {"qa_id":"QA:5366b0e4eb04de43aa00dc07","qa_group_id":"QAG:eaa3ca06613424600fc5a009","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Moreover, in a phase 3 trial (JACOB), metastatic G/GEJ cancer pati... |
QA:555c26aef23de6e95482e0b3 | QAG:0ab1f673aa79e2b66f130076 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10092493? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10092493","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10092493"
] | [] | [] | [] | {"qa_id":"QA:555c26aef23de6e95482e0b3","qa_group_id":"QAG:0ab1f673aa79e2b66f130076","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1009249... |
QA:5665d3da090f49c7e59d3852 | QAG:3f21210fcd027e10b3a76e94 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Patients were eligible if they were aged ≥ 20 years, had unresectable or metastatic, histologically confirmed G/GEJ adenocarcinoma received ≥ 2 previous chemotherapy regimens, were refractory to or intolerant of standard therapy in the advanced or recurrent setting, ha... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9df7782f9b04d50e7975e8db","quotes":["Patients were eligible if they were aged ≥ 20 years, had unresectable or met... | [
"CLM:9df7782f9b04d50e7975e8db",
"CLM:3dd0f0d29cb356f9a00a37ce"
] | [
"PMCID:PMC6942596"
] | [
"SPAN:a34d314bb53b97b9daec0563"
] | [] | [] | {"qa_id":"QA:5665d3da090f49c7e59d3852","qa_group_id":"QAG:3f21210fcd027e10b3a76e94","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Patients were eligible if they were aged ≥ 20 years, had unresecta... |
QA:5a3402f26730455cd2fc64ba | QAG:89c5d5c026b3c8862790b95e | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "In ATTRACTION-2, a double-blind, placebo-controlled, randomized phase III study in patients with unresectable advanced or recurrent G/GEJ cancer refractory to or intolerant of ≥2 prior chemotherapy regimens, nivolumab monotherapy led to a significantly longer OS versus... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dec01f52791478c4dca2ca20","quotes":["In ATTRACTION-2, a double-blind, placebo-controlled, randomized phase III st... | [
"CLM:dec01f52791478c4dca2ca20",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC6386029"
] | [
"SPAN:62615bc84d2795a1ffbcc4bb"
] | [] | [] | {"qa_id":"QA:5a3402f26730455cd2fc64ba","qa_group_id":"QAG:89c5d5c026b3c8862790b95e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"In ATTRACTION-2, a double-blind, placebo-controlled, randomized ph... |
QA:61bcdab84eb59ec2e9db6444 | QAG:b61487723f6553f210ebefc4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "1 Although the incidence rate has declined and survival has improved in recent years, G/GEJ cancer remains the second most common cancer and the second leading cause of cancer death in China, with a poor prognosis"? Return the original wording with paper, Claim, and Ev... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0875f866fad4f04736f39a4d","quotes":["1 Notably, almost half of the total case of G/GEJ cancer occurs in East Asia... | [
"CLM:0875f866fad4f04736f39a4d",
"CLM:266e6db0a42e073cd5cbc5df"
] | [
"PMCID:PMC7781732"
] | [
"SPAN:c493b126a4fdb52336bc63af"
] | [] | [] | {"qa_id":"QA:61bcdab84eb59ec2e9db6444","qa_group_id":"QAG:b61487723f6553f210ebefc4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"1 Although the incidence rate has declined and survival has improv... |
QA:6584c55b916e2b7d7fa5fd70 | QAG:5d42adcefc359b0e79606f77 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "In pretreated patients, ramucirumab in combination with pembrolizumab was associated with promising survival and prolonged PFS for patients with PD-L1-positive tumors (per an investigational version of the 22C3 assay) compared with patients with PD-L1-negative tumors i... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e38b8cdd054258f3acd3fbf4","quotes":["In pretreated patients, ramucirumab in combination with pembrolizumab was as... | [
"CLM:e38b8cdd054258f3acd3fbf4",
"CLM:03ccfa8216f57bebab8dab3a"
] | [
"PMCID:PMC7602637"
] | [
"SPAN:e53e7d143d0e35c3da53408d"
] | [] | [] | {"qa_id":"QA:6584c55b916e2b7d7fa5fd70","qa_group_id":"QAG:5d42adcefc359b0e79606f77","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"In pretreated patients, ramucirumab in combination with pembrolizu... |
QA:6884c0fe92c038c0cea63454 | QAG:ac68c40fd1b563343d631676 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Patients must have received treatment with two or more lines of previous chemotherapy in the advanced or recurrent setting, have an ECOG performance status of 0 or 1, and a life expectancy of at least 3 months"? Return the original wording with paper, Claim, and Eviden... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:49f58b272a655608d6363f48","quotes":["Patients must have received treatment with two or more lines of previous che... | [
"CLM:49f58b272a655608d6363f48",
"CLM:07188d589c90a9f6b66a8e97"
] | [
"PMCID:PMC7165140"
] | [
"SPAN:de762ea98fc078a9c0eb1d80",
"SPAN:e41df9c3b7de5fbb6f4edacf"
] | [] | [] | {"qa_id":"QA:6884c0fe92c038c0cea63454","qa_group_id":"QAG:ac68c40fd1b563343d631676","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Patients must have received treatment with two or more lines of pr... |
QA:68e1005395f3f8ebbe47ce82 | QAG:cf8ed098bc60340310e231b2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "reported that PD-1/PD-L1 inhibitors were more effective than control therapy in the treatment of esophageal or G/GEJ cancer, demonstrating increased pooled odds ratios (ORs) for OS and PFS"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ee8eecad09c46902fad2aa14","quotes":["In contrast, Chen et al. [ 6 ] reported that PD-1/PD-L1 inhibitors were more... | [
"CLM:ee8eecad09c46902fad2aa14",
"CLM:6bf05ebcab646cbcedadb313"
] | [
"PMCID:PMC8397221"
] | [
"SPAN:ad551d2574439e69b4dc4dd6"
] | [] | [] | {"qa_id":"QA:68e1005395f3f8ebbe47ce82","qa_group_id":"QAG:cf8ed098bc60340310e231b2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"reported that PD-1/PD-L1 inhibitors were more effective than contr... |
QA:6f0540aa239f8755635f999c | QAG:a983db4127e164f039b0ff83 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "A previous study reported that another PD-1 inhibitor, sintilimab, combined with CapeOx also achieved a 19.4% pCR rate and a 47.2% MPR rate, indicating that chemotherapy combined with ICB drugs has great application potential in neoadjuvant therapy for advanced G/GEJ c... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7e121d77698c955a083da177","quotes":["A previous study reported that another PD-1 inhibitor, sintilimab, combined ... | [
"CLM:7e121d77698c955a083da177",
"CLM:6e9c0ee57fac704864253bf1"
] | [
"PMCID:PMC9491115"
] | [
"SPAN:f5febc054c53836d081f99cf"
] | [] | [] | {"qa_id":"QA:6f0540aa239f8755635f999c","qa_group_id":"QAG:a983db4127e164f039b0ff83","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"A previous study reported that another PD-1 inhibitor, sintilimab,... |
QA:700089fc0c400d88bab15dcb | QAG:7404dd3032beca15c3942d8a | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34553222? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:34553222","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:34553222"
] | [] | [] | [] | {"qa_id":"QA:700089fc0c400d88bab15dcb","qa_group_id":"QAG:7404dd3032beca15c3942d8a","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34553222? E... |
QA:70a9dd491491efaa793482ab | QAG:e3281a72a26fd5d864ca5dd9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "In the past decades, therapeutic advances such as targeted drugs and ICB inhibitors have improved the outcomes of metastatic gastric cancer patients, but the prognosis of resectable gastric cancer remains poor and the therapy strategy was controversial between Western ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d2037129247ea9e35acbb8c8","quotes":["In the past decades, therapeutic advances such as targeted drugs and ICB inh... | [
"CLM:d2037129247ea9e35acbb8c8",
"CLM:03ccfa8216f57bebab8dab3a"
] | [
"PMCID:PMC9491115"
] | [
"SPAN:6d93fa88b72520b7ffad9cbd"
] | [] | [] | {"qa_id":"QA:70a9dd491491efaa793482ab","qa_group_id":"QAG:e3281a72a26fd5d864ca5dd9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"In the past decades, therapeutic advances such as targeted drugs a... |
QA:7a2ca2c611a4645766371547 | QAG:8c602926a4588553867d497e | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "3–5 Although several clinical trials have investigated the efficacy of targeted agents plus chemotherapy as first-line treatment, including trastuzumab, 6 lapatinib, 7 bevacizumab, 8 rilotumumab 9 and ramucirumab, 10 only trastuzumab improved overall survival of up to ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:619cf140fcdd7c535b17a748","quotes":["3–5 Although several clinical trials have investiga... | [
"CLM:619cf140fcdd7c535b17a748",
"CLM:9f172befde69a97c82fb9a26",
"CLM:9101e1935c3e1afe70e5e8d5"
] | [
"PMCID:PMC7781732",
"PMCID:PMC7602637"
] | [
"SPAN:4ae33b94f6a1c28552744dd4",
"SPAN:1d228c1c957dbe15dd5100b1"
] | [
"ASC2:4538ac9f5c8c8bdc796884c8"
] | [
"HYP:DCH:06cd044d85c3b22db246afbf"
] | {"qa_id":"QA:7a2ca2c611a4645766371547","qa_group_id":"QAG:8c602926a4588553867d497e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"3–5 Although several clinical trials have investigated the efficac... |
QA:7aae1184782e7cf3c2f4dce8 | QAG:5e643a81eec30cef9fef2c0e | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "thus, we need to prolong the follow-up time to determine whether adding tislelizumab to the neoadjuvant SOX regimen increased the prognosis of advanced G/GEJ patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5087ace6da05adef0239a3d3","quotes":["Firstly, although a previous retrospective study demonstrated that advanced ... | [
"CLM:5087ace6da05adef0239a3d3",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC9491115"
] | [
"SPAN:08544aba2c676e1244803362"
] | [] | [] | {"qa_id":"QA:7aae1184782e7cf3c2f4dce8","qa_group_id":"QAG:5e643a81eec30cef9fef2c0e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"thus, we need to prolong the follow-up time to determine whether a... |
QA:80720f8cc0acb1e6dec04f9c | QAG:2cab0f3274891850e38fa270 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:33446564? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:33446564","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:33446564"
] | [] | [] | [] | {"qa_id":"QA:80720f8cc0acb1e6dec04f9c","qa_group_id":"QAG:2cab0f3274891850e38fa270","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:33446564? E... |
QA:849ca8cbbed2cb1ba0a0c181 | QAG:a7e2dd6ef1d4f6f3d424c8b8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "6 months, respectively, in KEYNOTE-062) for PD-L1 CPS ≥ 1 patients was lower than rates initially reported in the first-line monotherapy arm phase 2 study (KEYNOTE-059: ORR, 25.8%; OS, 20.7 months) , pembrolizumab alone was noninferior to chemotherapy for OS as first-l... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7756c7eb9c9a293fdf7ace4b","quotes":["Although response rate and median OS (14.5% and 10.... | [
"CLM:7756c7eb9c9a293fdf7ace4b",
"CLM:3add2a9d54141ff5edee4d18",
"CLM:58d386d4a0845d393f804d59",
"CLM:a8b5776b5fe1fba8b5179e8f",
"CLM:6023b413da1c5cd5fbdd1941"
] | [
"PMCID:PMC7602637",
"PMCID:PMC10314681",
"PMCID:PMC9299889"
] | [
"SPAN:065d91a50a8c92664c267491",
"SPAN:4f94eb6f1e8292ced2206fad",
"SPAN:4fc4500998a96dc899f4301d",
"SPAN:8c752a5a65c1756d9ef97b3d"
] | [
"ASC2:11caab21cb5a540f3966da6b",
"ASC2:45ffcb29d92e94fe93bd1a0f"
] | [
"HYP:DCH:85e93a82d0e9429bff14d669"
] | {"qa_id":"QA:849ca8cbbed2cb1ba0a0c181","qa_group_id":"QAG:a7e2dd6ef1d4f6f3d424c8b8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"6 months, respectively, in KEYNOTE-062) for PD-L1 CPS ≥ 1 patients... |
QA:85ba3d836813f47846fcc58b | QAG:1dca690e4d59aa4b0d069914 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "14 Camrelizumab combined with trastuzumab and chemotherapy led to a higher ORR than trastuzumab plus chemotherapy for HER2-positive advanced gastric cancer (75% versus 46.2% p = 0.032), according to a retrospective study"? Return the original wording with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:03ccfa8216f57bebab8dab3a","quotes":["14 Camrelizumab combined w... | [
"CLM:03ccfa8216f57bebab8dab3a",
"CLM:072282e1a03a6f258ddcaf17",
"CLM:f95decb613def88b07140339",
"CLM:d1b34479a4fc86ef092eed94"
] | [
"PMCID:PMC10679498",
"PMID:32208960",
"PMCID:PMC9813086"
] | [
"SPAN:815d5f1783c4d45961adc9b2",
"SPAN:81af4047476e0e460ed72bde",
"SPAN:9b430e4a86c6aa4c607a71d7",
"SPAN:a78ff7d9ac862e98905c06d6"
] | [
"ASC2:4730b6a16321432857956804",
"ASC2:92ae0b3691ec687b07b8780a"
] | [
"HYP:DCH:b4a155d0ec3f6bbcce7d7e97"
] | {"qa_id":"QA:85ba3d836813f47846fcc58b","qa_group_id":"QAG:1dca690e4d59aa4b0d069914","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"14 Camrelizumab combined with trastuzumab and chemotherapy led to ... |
QA:869a323221e41fa496dca378 | QAG:e73d89d2db1e5f89078a48c0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Another limitation is that the comparison arm received paclitaxel alone when paclitaxel plus ramucirumab is currently one of the standard‐of‐care therapies available for patients with advanced gastric cancer whose disease progressed on chemotherapy; this therapy option... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6023b413da1c5cd5fbdd1941","quotes":["Another limitation is that the comparison arm recei... | [
"CLM:6023b413da1c5cd5fbdd1941",
"CLM:072282e1a03a6f258ddcaf17",
"CLM:a8b5776b5fe1fba8b5179e8f"
] | [
"PMCID:PMC9299889",
"PMCID:PMC7602637"
] | [
"SPAN:8c752a5a65c1756d9ef97b3d",
"SPAN:4fc4500998a96dc899f4301d"
] | [
"ASC2:45ffcb29d92e94fe93bd1a0f"
] | [
"HYP:DCH:d1abecb0facd9723287afed0"
] | {"qa_id":"QA:869a323221e41fa496dca378","qa_group_id":"QAG:e73d89d2db1e5f89078a48c0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Another limitation is that the comparison arm received paclitaxel ... |
QA:87fb86eac3a36661338e7448 | QAG:c346354edc4830f21929cebe | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "STK11 mutations was associated with primary resistance to PD-1/PD-L1 agents in non-small cell lung cancer; however, their role in metastatic gastric cancer has not been well established"? Return the original wording with paper, Claim, and Evidence Span references.
Int... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:72e310755f971cfbfcff6949","quotes":["STK11 mutations are associated with primary resista... | [
"CLM:72e310755f971cfbfcff6949",
"CLM:03ccfa8216f57bebab8dab3a",
"CLM:685d093fc973a58e3e19dad5"
] | [
"PMCID:PMC9501109",
"PMCID:PMC6882659"
] | [
"SPAN:9c3fae57137ff0cc2e2aec8a",
"SPAN:d352cd023c16005c02046b8f"
] | [
"ASC2:876f51b69ddb921ec05504b9"
] | [
"HYP:DCH:1971108a9eb5b4e28f6df438"
] | {"qa_id":"QA:87fb86eac3a36661338e7448","qa_group_id":"QAG:c346354edc4830f21929cebe","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"STK11 mutations was associated with primary resistance to PD-1/PD-... |
QA:8ad1025f71fe85ef9321be81 | QAG:6cb7d08897652fce0f4e2511 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "22 , 23 One potential limitation of KEYNOTE‐061 was that the comparison arm received paclitaxel alone when paclitaxel plus ramucirumab had shown superior OS compared with paclitaxel, although these data were not available at the initiation of the study; paclitaxel plus... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5de3f7118846b520e68dd9bf","quotes":["22 , 23 One potential limitation of KEYNOTE‐061 was that the comparison arm ... | [
"CLM:5de3f7118846b520e68dd9bf",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC9299889"
] | [
"SPAN:a96e17a431134bedb78e56a8"
] | [] | [] | {"qa_id":"QA:8ad1025f71fe85ef9321be81","qa_group_id":"QAG:6cb7d08897652fce0f4e2511","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"22 , 23 One potential limitation of KEYNOTE‐061 was that the compa... |
QA:9082bdeed39772f6764d2cf5 | QAG:0c8291e2f888d588551f587e | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Results Between October 2018 and September 2019, a total of 58 patients with advanced G/GEJ cancer were enrolled in this study"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supportin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c872a5ce654c14c62648234e","quotes":["The primary end point was objective response rate (ORR) as assessed accordin... | [
"CLM:c872a5ce654c14c62648234e",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC7566427"
] | [
"SPAN:2516b7b9cb3e9e9d595647bb"
] | [] | [] | {"qa_id":"QA:9082bdeed39772f6764d2cf5","qa_group_id":"QAG:0c8291e2f888d588551f587e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Results Between October 2018 and September 2019, a total of 58 pat... |
QA:9caa8972c2350193ce41b31f | QAG:7de1c076b2783c6a514cd2f1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Patients received avelumab every 2 weeks intravenously at 3, 10, or 20 mg/kg during dose escalation and 10 mg/kg during dose expansion"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9f172befde69a97c82fb9a26","quotes":["Patients received avelumab every 2 weeks intravenously at 3, 10, or 20 mg/kg... | [
"CLM:9f172befde69a97c82fb9a26",
"CLM:03ccfa8216f57bebab8dab3a"
] | [
"PMCID:PMC6570778"
] | [
"SPAN:03f755366d173f13c90b8f46",
"SPAN:8997e55bdff34a7b2a0f098c"
] | [] | [] | {"qa_id":"QA:9caa8972c2350193ce41b31f","qa_group_id":"QAG:7de1c076b2783c6a514cd2f1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Patients received avelumab every 2 weeks intravenously at 3, 10, o... |
QA:9ef14cb29f989ae5665a18a8 | QAG:37c6be438668ab8257dbd5e9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Conclusions RC48 showed promising activity with manageable safety, suggesting potential application in patients with HER2‐overexpressing, advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy"? Return the o... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bf8fc1b65ed6434f6490294d","quotes":["Conclusions RC48 showed promising activity with manageable safety, suggestin... | [
"CLM:bf8fc1b65ed6434f6490294d",
"CLM:07188d589c90a9f6b66a8e97"
] | [
"PMCID:PMC8626607"
] | [
"SPAN:227f489d458e806a2c915318"
] | [] | [] | {"qa_id":"QA:9ef14cb29f989ae5665a18a8","qa_group_id":"QAG:37c6be438668ab8257dbd5e9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Conclusions RC48 showed promising activity with manageable safety,... |
QA:a6c9c64b04271213272f2557 | QAG:10fc701fe279ce71ae924faa | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Conclusion The TBP strategy failed to meet PFS in patients with HER2-positive advanced G/GEJ cancer, and no beneficial biomarkers were found"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the e... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8c6758936c08b72928d88b5a","quotes":["Conclusion The TBP strategy failed to improve PFS in patients with HER2-posi... | [
"CLM:8c6758936c08b72928d88b5a",
"CLM:3dd0f0d29cb356f9a00a37ce"
] | [
"PMID:32208960"
] | [
"SPAN:bd2f2273651bca1b6e49d7b6"
] | [] | [] | {"qa_id":"QA:a6c9c64b04271213272f2557","qa_group_id":"QAG:10fc701fe279ce71ae924faa","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Conclusion The TBP strategy failed to meet PFS in patients with HE... |
QA:aca11eb821778e43822cc5bf | QAG:cd4c52918f8dbccc7bd7adb3 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6362598? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6362598","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6362598"
] | [] | [] | [] | {"qa_id":"QA:aca11eb821778e43822cc5bf","qa_group_id":"QAG:cd4c52918f8dbccc7bd7adb3","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6362598... |
QA:acd2c973d43a227d9bdf09c5 | QAG:53404cd3d263d513eee8b288 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "After the KEYNOTE‐063 study began, results of the global KEYNOTE‐061 study ( NCT02370498 ) showed that pembrolizumab did not improve OS compared with paclitaxel in patients previously treated for advanced gastric cancer"? Return the original wording with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ad5fd93ec5c8b75768d1e7b3","quotes":["After the KEYNOTE‐063 study began, results of the global KEYNOTE‐061 study (... | [
"CLM:ad5fd93ec5c8b75768d1e7b3",
"CLM:07188d589c90a9f6b66a8e97"
] | [
"PMCID:PMC9299889"
] | [
"SPAN:8f415d1c7af5dbfb8aae8362"
] | [] | [] | {"qa_id":"QA:acd2c973d43a227d9bdf09c5","qa_group_id":"QAG:53404cd3d263d513eee8b288","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"After the KEYNOTE‐063 study began, results of the global KEYNOTE‐0... |
QA:b02c7d802095eb638adf3051 | QAG:91fda4442ec357288799f7fc | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Anti-PD-1 and PD-L1 use was not associated with SAE development in esophageal or G/GEJ cancer patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Cl... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7c642ae7a53b65c6b9f0e2a5","quotes":["Anti-PD-1 and PD-L1 use was not significantly associated with SAE developmen... | [
"CLM:7c642ae7a53b65c6b9f0e2a5",
"CLM:03ccfa8216f57bebab8dab3a"
] | [
"PMCID:PMC8397221"
] | [
"SPAN:c4e39782e6b08bfeaf0e430e"
] | [] | [] | {"qa_id":"QA:b02c7d802095eb638adf3051","qa_group_id":"QAG:91fda4442ec357288799f7fc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Anti-PD-1 and PD-L1 use was not associated with SAE development in... |
QA:b0e269c94018d7cf41fb81ea | QAG:c811513070bdd6db33da3ef1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "(3) the intervention group received PD-1/PD-L1 inhibitor without combination except standard of care (SOC) treatment; (4) the control group was selected whose definition was an SOC treatment recommended by the National Comprehensive Cancer Network (NCCN) guidelines or ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b1e271353e1dceabac1155f3","quotes":["For inclusion in this study, the selected literatur... | [
"CLM:b1e271353e1dceabac1155f3",
"CLM:07188d589c90a9f6b66a8e97",
"CLM:685d093fc973a58e3e19dad5"
] | [
"PMCID:PMC8397221",
"PMCID:PMC6882659"
] | [
"SPAN:bafcbacb51e76a433e87a5c0",
"SPAN:d352cd023c16005c02046b8f"
] | [
"ASC2:5cbb1a1c35e265b6385dd695"
] | [
"HYP:DCH:183cc89f6d0271d1851e7d61"
] | {"qa_id":"QA:b0e269c94018d7cf41fb81ea","qa_group_id":"QAG:c811513070bdd6db33da3ef1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"(3) the intervention group received PD-1/PD-L1 inhibitor without c... |
QA:b90dd86be8e943f9947bc5f9 | QAG:9c1867efd782c29ff8e142b3 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35689885? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:35689885","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:35689885"
] | [] | [] | [] | {"qa_id":"QA:b90dd86be8e943f9947bc5f9","qa_group_id":"QAG:9c1867efd782c29ff8e142b3","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35689885? E... |
QA:bc86e70ed3cc333a25e8635c | QAG:7cef2a05ca68b7e050d235e8 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC11065504? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC11065504","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC11065504"
] | [] | [] | [] | {"qa_id":"QA:bc86e70ed3cc333a25e8635c","qa_group_id":"QAG:7cef2a05ca68b7e050d235e8","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1106550... |
QA:be297cc355e976e7b547709e | QAG:10281dfdfa454e6b8d7af7b1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Nivolumab is recommended as a third-line or later-line therapy in gastric cancer patients who are likely to have received trastuzumab"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact su... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cf4c0594bf7604cbf76f1a1d","quotes":["Nivolumab is recommended as a third-line or later-line therapy in gastric ca... | [
"CLM:cf4c0594bf7604cbf76f1a1d",
"CLM:072282e1a03a6f258ddcaf17"
] | [
"PMCID:PMC6942596"
] | [
"SPAN:33793eb109766fe90ff7a382"
] | [] | [] | {"qa_id":"QA:be297cc355e976e7b547709e","qa_group_id":"QAG:10281dfdfa454e6b8d7af7b1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Nivolumab is recommended as a third-line or later-line therapy in ... |
QA:c0ac8d33dd3af3398a9015a1 | QAG:3363835242ee4b9ca80c278f | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "44 Moreover, anti-VEGF-A (bevacizumab) treatment in colorectal cancer patients decreased Treg proportions in peripheral blood"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:95d41e05d4e2fc79154ac370","quotes":["44 Moreover, anti-VEGF-A (bevacizumab) treatment in colorectal cancer patien... | [
"CLM:95d41e05d4e2fc79154ac370",
"CLM:03ccfa8216f57bebab8dab3a"
] | [
"PMCID:PMC10353329"
] | [
"SPAN:6226fa01e99307c73740be14"
] | [] | [] | {"qa_id":"QA:c0ac8d33dd3af3398a9015a1","qa_group_id":"QAG:3363835242ee4b9ca80c278f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"44 Moreover, anti-VEGF-A (bevacizumab) treatment in colorectal can... |
QA:c33a9f09cf4746f7bbb14113 | QAG:372b1802f4237b6773f014fe | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Previous clinical trials ( 8 , 9 , 24 ) demonstrated that the PD-L1 CPS score was a useful marker to predict therapeutic response in ICB monotherapy in many cancer types, and MSI-H/dMMR and EBV infection was correlated with more tumor-infiltrating lymphocytes (TILs) an... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c447e9ea89dd12c165180905","quotes":["Previous clinical trials ( 8 , 9 , 24 ) demonstrate... | [
"CLM:c447e9ea89dd12c165180905",
"CLM:03ccfa8216f57bebab8dab3a",
"CLM:7756c7eb9c9a293fdf7ace4b"
] | [
"PMCID:PMC9491115",
"PMCID:PMC7602637"
] | [
"SPAN:a0247f17b15d7781781af976",
"SPAN:065d91a50a8c92664c267491"
] | [
"ASC2:07fc9742bb78726472da1b22"
] | [] | {"qa_id":"QA:c33a9f09cf4746f7bbb14113","qa_group_id":"QAG:372b1802f4237b6773f014fe","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Previous clinical trials ( 8 , 9 , 24 ) demonstrated that the PD-L... |
QA:c8a171d50d0b209fbf8db361 | QAG:a087dedae03dad184499002a | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "4 Findings from our meta-analysis suggested that PD-1/PD-L1 inhibitors did not improve the relative risk of death compared with chemotherapy in patients with advanced gastric or gastroesophageal junction cancer after at least 1 line of standard chemotherapy"? Return th... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:685d093fc973a58e3e19dad5","quotes":["4 Findings from our meta-analysis suggested that PD-1/PD-L1 inhibitors did n... | [
"CLM:685d093fc973a58e3e19dad5",
"CLM:07188d589c90a9f6b66a8e97"
] | [
"PMCID:PMC6882659"
] | [
"SPAN:d352cd023c16005c02046b8f"
] | [] | [] | {"qa_id":"QA:c8a171d50d0b209fbf8db361","qa_group_id":"QAG:a087dedae03dad184499002a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"4 Findings from our meta-analysis suggested that PD-1/PD-L1 inhibi... |
QA:c996f179c9f2d9e335af266a | QAG:26a921c9619993fac7ba8682 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Between October 2018 and September 2019, a total of 58 patients with advanced G/GEJ cancer were enrolled from 11 centers in China"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppor... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:45901511eba78e74abb76154","quotes":["Between October 2018 and September 2019, a total of 58 patients with advance... | [
"CLM:45901511eba78e74abb76154",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC7566427"
] | [
"SPAN:b5c3ee2b685e7659eb8b6f64"
] | [] | [] | {"qa_id":"QA:c996f179c9f2d9e335af266a","qa_group_id":"QAG:26a921c9619993fac7ba8682","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Between October 2018 and September 2019, a total of 58 patients wi... |
QA:ceeef58e8115a97c0dd48b80 | QAG:7509ac7e2492d9bc4d33960b | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6682857? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6682857","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6682857"
] | [] | [] | [] | {"qa_id":"QA:ceeef58e8115a97c0dd48b80","qa_group_id":"QAG:7509ac7e2492d9bc4d33960b","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6682857... |
QA:d94a3acab8f4c6f392e702fa | QAG:f89e332147e737eb11e2127c | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Here, we report the results from the first-line cohort (Cohort A2) of patients with advanced or metastatic G/GEJ cancer and PD-L1-positive or –negative tumors who received ramucirumab plus pembrolizumab"? Return the original wording with paper, Claim, and Evidence Span... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a8b5776b5fe1fba8b5179e8f","quotes":["Here, we report the results from the first-line cohort (Cohort A2) of patien... | [
"CLM:a8b5776b5fe1fba8b5179e8f",
"CLM:3dd0f0d29cb356f9a00a37ce"
] | [
"PMCID:PMC7602637"
] | [
"SPAN:4fc4500998a96dc899f4301d"
] | [] | [] | {"qa_id":"QA:d94a3acab8f4c6f392e702fa","qa_group_id":"QAG:f89e332147e737eb11e2127c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Here, we report the results from the first-line cohort (Cohort A2)... |
QA:dd003a6edc6926e612906f7c | QAG:99929d24ebd44f8fbfec6ad6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "It has been reported that the concurrence of HER2-positive status and diffuse subtype gastric cancer was associated with the worst survival outcomes"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retu... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c77aed877294af21b0116b82","quotes":["It has been reported that the concurrence of HER2-p... | [
"CLM:c77aed877294af21b0116b82",
"CLM:07188d589c90a9f6b66a8e97",
"CLM:ff9be70a993bbca45ec926d9",
"CLM:43cde8df325291a4af2574ba",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC6591878",
"PMCID:PMC9813086",
"PMCID:PMC10679498"
] | [
"SPAN:450bafc94877f61e9c73b91e",
"SPAN:a0c8a381518c85cb2105251c",
"SPAN:d8d0e7f7f322ebd33a408d9c",
"SPAN:ab8a8d2763f48c350ba97a29"
] | [
"ASC2:e5d0d2f7b379946c65e4e0da",
"ASC2:16ed5098d20a410f7f2244fd"
] | [
"HYP:DCH:f5b31354272b3f17f093c9ae"
] | {"qa_id":"QA:dd003a6edc6926e612906f7c","qa_group_id":"QAG:99929d24ebd44f8fbfec6ad6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"It has been reported that the concurrence of HER2-positive status ... |
QA:e204c633925d448cd869459a | QAG:2985ca3d9cd71e01904106a7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "29 For example, ERBB2/4 mutations was associated with rapid progression under trastuzumab therapy in HER2-positive metastatic gastric cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the e... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3add2a9d54141ff5edee4d18","quotes":["29 For example, ERBB2/4 mutations were associated w... | [
"CLM:3add2a9d54141ff5edee4d18",
"CLM:072282e1a03a6f258ddcaf17",
"CLM:c77aed877294af21b0116b82"
] | [
"PMCID:PMC10679498",
"PMCID:PMC6591878"
] | [
"SPAN:ab8a8d2763f48c350ba97a29",
"SPAN:450bafc94877f61e9c73b91e"
] | [
"ASC2:16ed5098d20a410f7f2244fd"
] | [
"HYP:DCH:c545702277751ed346689b08"
] | {"qa_id":"QA:e204c633925d448cd869459a","qa_group_id":"QAG:2985ca3d9cd71e01904106a7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"29 For example, ERBB2/4 mutations was associated with rapid progre... |
QA:e3522bec3e5cf82a1ca7f929 | QAG:81ea3745c878674380f58bb0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "2 Studies eligible for inclusion met all of the following criteria: (1) prospective clinical trials in patients with gastric or gastroesophageal junction cancer, (2) participants in immunotherapy arm received a single anti-PD-1/PD-L1 agent, (3) antitumor activity and s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6e9c0ee57fac704864253bf1","quotes":["2.2 Studies eligible for inclusion met all of the following criteria: (1) pr... | [
"CLM:6e9c0ee57fac704864253bf1",
"CLM:03ccfa8216f57bebab8dab3a"
] | [
"PMCID:PMC6882659"
] | [
"SPAN:00bb630b09f9c5e7642de3c8"
] | [] | [] | {"qa_id":"QA:e3522bec3e5cf82a1ca7f929","qa_group_id":"QAG:81ea3745c878674380f58bb0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"2 Studies eligible for inclusion met all of the following criteria... |
QA:e73f9a31c2133c4519396308 | QAG:bc6806e88e822f6e0615f32a | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Patients were assigned to the paclitaxel (80 mg/m 2 , days 1, 8, and 15, every 4 weeks) or paclitaxel with trastuzumab (PT; initially 8 mg/kg followed by 6 mg/kg, every 3 weeks) arms. The primary endpoint was progression-free survival (PFS)"? Return the original wordin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f95decb613def88b07140339","quotes":["Patients were randomly assigned to the paclitaxel (... | [
"CLM:f95decb613def88b07140339",
"CLM:3dd0f0d29cb356f9a00a37ce",
"CLM:ff9be70a993bbca45ec926d9"
] | [
"PMID:32208960",
"PMCID:PMC6591878"
] | [
"SPAN:81af4047476e0e460ed72bde",
"SPAN:9b430e4a86c6aa4c607a71d7",
"SPAN:d8d0e7f7f322ebd33a408d9c"
] | [
"ASC2:c632b1956748b284e136692c"
] | [
"HYP:DCH:1c7310f7f8d8ed28dd486d6b"
] | {"qa_id":"QA:e73f9a31c2133c4519396308","qa_group_id":"QAG:bc6806e88e822f6e0615f32a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Patients were assigned to the paclitaxel (80 mg/m 2 , days 1, 8, a... |
QA:e7f0a1dcc3aad7992b000055 | QAG:98daf0f93f57710508838a94 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9850086? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9850086","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9850086"
] | [] | [] | [] | {"qa_id":"QA:e7f0a1dcc3aad7992b000055","qa_group_id":"QAG:98daf0f93f57710508838a94","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9850086... |
QA:ead091baef1028ddaaa425ef | QAG:1c0a1887d2da7b58d582bce2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "32 In conclusion, this exploratory analysis from the phase 3 KEYNOTE-061 trial showed that tumor Tcell inf GEP as a continuous variable was associated with clinical outcomes with second-line pembrolizumab in advanced G/GEJ cancer"? Return the original wording with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:58d386d4a0845d393f804d59","quotes":["32 In conclusion, this exploratory analysis from th... | [
"CLM:58d386d4a0845d393f804d59",
"CLM:3add2a9d54141ff5edee4d18",
"CLM:6ee7ab0c2b485e3cec13aff8",
"CLM:072282e1a03a6f258ddcaf17",
"CLM:7756c7eb9c9a293fdf7ace4b"
] | [
"PMCID:PMC10314681",
"PMCID:PMC7602637",
"PMCID:PMC8397221"
] | [
"SPAN:4f94eb6f1e8292ced2206fad",
"SPAN:0ab3c196ce00c5481ec81caa",
"SPAN:b090b5b651896cb19b6ff8b3",
"SPAN:065d91a50a8c92664c267491"
] | [
"ASC2:3bd33acc30cde3d844aa36e3",
"ASC2:11caab21cb5a540f3966da6b"
] | [
"HYP:DCH:54cd4e572a225389f9624d29"
] | {"qa_id":"QA:ead091baef1028ddaaa425ef","qa_group_id":"QAG:1c0a1887d2da7b58d582bce2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"32 In conclusion, this exploratory analysis from the phase 3 KEYNO... |
QA:ee600031759ebf335ba25cc1 | QAG:a67cfa4bc3d1c251492c671a | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "As the first-line palliative chemotherapy treatment in the phase 3 trial (TRIO-013/LOGiC), patients with HER2+ advanced G/GEJ cancer received lapatinib (an anti-HER2 agent) or placebo in combination with capecitabine plus oxaliplatin (CapeOX); OS was not significantly ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:db0a3ca7fd4bb856e048f882","quotes":["As the first-line palliative chemotherapy treatment in the phase 3 trial (TR... | [
"CLM:db0a3ca7fd4bb856e048f882",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC6942596"
] | [
"SPAN:83f3fd1c82daebcd326af396"
] | [] | [] | {"qa_id":"QA:ee600031759ebf335ba25cc1","qa_group_id":"QAG:a67cfa4bc3d1c251492c671a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"As the first-line palliative chemotherapy treatment in the phase 3... |
QA:f4ca4393ec74b1ab9c76daeb | QAG:f8be2a56161d2e3de0054668 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "In conclusion, our analysis revealed that PD-1/PD-L1 inhibitors prolonged the OS as compared to the control, while no significant effect on the PFS was observed in patients with esophageal or G/GEJ cancer"? Return the original wording with paper, Claim, and Evidence Sp... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f7b8e5ff3d8f869bdcac3fda","quotes":["In conclusion, our analysis revealed that PD-1/PD-L1 inhibitors significantl... | [
"CLM:f7b8e5ff3d8f869bdcac3fda",
"CLM:03ccfa8216f57bebab8dab3a"
] | [
"PMCID:PMC8397221"
] | [
"SPAN:a79b76ccfebaae513a06d346"
] | [] | [] | {"qa_id":"QA:f4ca4393ec74b1ab9c76daeb","qa_group_id":"QAG:f8be2a56161d2e3de0054668","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"In conclusion, our analysis revealed that PD-1/PD-L1 inhibitors pr... |
QA:f4d0e09f3edc0934199ce4d2 | QAG:c55d0eebc716d8c6090420ec | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Twenty-eight treatment-naïve patients with advanced/metastatic G/GEJ adenocarcinoma received ramucirumab plus pembrolizumab in this phase 1a/b trial"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retu... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:abce88732da30f5f5b7dfa33","quotes":["Twenty-eight treatment-naïve patients with advanced/metastatic G/GEJ adenoca... | [
"CLM:abce88732da30f5f5b7dfa33",
"CLM:3dd0f0d29cb356f9a00a37ce"
] | [
"PMCID:PMC7602637"
] | [
"SPAN:63d58ad18410de62e9c3da17"
] | [] | [] | {"qa_id":"QA:f4d0e09f3edc0934199ce4d2","qa_group_id":"QAG:c55d0eebc716d8c6090420ec","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Twenty-eight treatment-naïve patients with advanced/metastatic G/G... |
QA:f8b826d0c1f1822340753cd9 | QAG:9bf26d3312cec57a370e4c6b | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Conclusions OS and PFS were numerically improved by adding pertuzumab to trastuzumab and chemotherapy as first-line treatment in Chinese HER2-positive gastric cancer/GEJC patients, and this regimen demonstrated an acceptable safety profile"? Return the original wording... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ff9be70a993bbca45ec926d9","quotes":["Conclusions OS and PFS were numerically improved by adding pertuzumab to tra... | [
"CLM:ff9be70a993bbca45ec926d9",
"CLM:0875f866fad4f04736f39a4d"
] | [
"PMCID:PMC6591878"
] | [
"SPAN:d8d0e7f7f322ebd33a408d9c"
] | [] | [] | {"qa_id":"QA:f8b826d0c1f1822340753cd9","qa_group_id":"QAG:9bf26d3312cec57a370e4c6b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Conclusions OS and PFS were numerically improved by adding pertuzu... |
QA:f920004296fbcd4a5a1d3ffc | QAG:83e5dbd44d50114da4878f8e | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Firstly, although a previous retrospective study demonstrated that advanced gastric cancer patients who achieved pCR had a better clinical outcome than non-pCR patients after adjuvant chemotherapy, the follow-up time of our study was short; thus, we need to prolong the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:82d014c5ee6c8c1a8771b19e","quotes":["Firstly, although a previous retrospective study demonstrated that advanced ... | [
"CLM:82d014c5ee6c8c1a8771b19e",
"CLM:3add2a9d54141ff5edee4d18"
] | [
"PMCID:PMC9491115"
] | [
"SPAN:08544aba2c676e1244803362"
] | [] | [] | {"qa_id":"QA:f920004296fbcd4a5a1d3ffc","qa_group_id":"QAG:83e5dbd44d50114da4878f8e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Firstly, although a previous retrospective study demonstrated that... |
QA:0006f6c664a7af67c00e7bc1 | QAG:84b40662d9c1082e4229601c | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "They found that the expression of LAYN was associated with increased levels of immune permeation of CD8 + T cells, CD4 + T cells, macrophages, neutrophils, and DCs in colon and gastric cancer"? Return the original wording with paper, Claim, and Evidence Span references... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ff1c06e6b3c741298e712193","quotes":["They found that the expression of LAYN was associated with increased levels ... | [
"CLM:ff1c06e6b3c741298e712193",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC6885872"
] | [
"SPAN:08b14fea9eabdb8d568282bc"
] | [] | [] | {"qa_id":"QA:0006f6c664a7af67c00e7bc1","qa_group_id":"QAG:84b40662d9c1082e4229601c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"They found that the expression of LAYN was associated with increas... |
QA:04b46e966e2ba46594a92765 | QAG:fc575508128e1f5d124bbc46 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Although camrelizumab combined with apatinib has achieved promising results in the treatment of various tumors, including hepatocellular carcinoma, osteosarcoma and triple-negative breast cancer, this regimen has not been reported in cholangiocarcinoma ( 16 , 17 , 19 )... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:350302ec6a501eaaeca57ed3","quotes":["Although camrelizumab combined with apatinib has achieved promising results ... | [
"CLM:350302ec6a501eaaeca57ed3",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC8071846"
] | [
"SPAN:e5d7f484cea54d9c3a7d1e90"
] | [] | [] | {"qa_id":"QA:04b46e966e2ba46594a92765","qa_group_id":"QAG:fc575508128e1f5d124bbc46","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Although camrelizumab combined with apatinib has achieved promisin... |
QA:078d09446bf16b60e30f90e1 | QAG:ad9c2573ccea5219dffa9e4f | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "With the start of the success of sotorasib in non-small-cell lung cancer (NSCLC), 1 sotorasib showed improved treatment outcomes in previously treated pancreatic cancer with 21% of objective response and 6.9 months of overall survival (OS)"? Return the original wording... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:01f48df2009a41f6aa528ef8","quotes":["With the start of the success of sotorasib in non-small-cell lung cancer (NS... | [
"CLM:01f48df2009a41f6aa528ef8",
"CLM:04a818b687b537542b6f6718"
] | [
"PMCID:PMC10164250"
] | [
"SPAN:0fc8a220ab03fcef09dd2f5b"
] | [] | [] | {"qa_id":"QA:078d09446bf16b60e30f90e1","qa_group_id":"QAG:ad9c2573ccea5219dffa9e4f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"With the start of the success of sotorasib in non-small-cell lung ... |
QA:0877fa08f98a7bde7aaaadec | QAG:ffb26d2704db0cdf3305bcd1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "12 In another basket trial, pembrolizumab led to 100% disease control in four patients with tumor DNA mismatch repair (MMR)-deficient cholangiocarcinoma"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a43de8973d470ec299b1f9f6","quotes":["12 In another basket trial, pembrolizumab resulted in 100% disease control i... | [
"CLM:a43de8973d470ec299b1f9f6",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC7269541"
] | [
"SPAN:b7ac3a69a1a89f04f3cdc705"
] | [] | [] | {"qa_id":"QA:0877fa08f98a7bde7aaaadec","qa_group_id":"QAG:ffb26d2704db0cdf3305bcd1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"12 In another basket trial, pembrolizumab led to 100% disease cont... |
QA:0fcf98283bd737378a480412 | QAG:bc04106ba8f94cb383e0535b | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Abstract Introduction The present study aims to evaluate the efficacy and safety of apatinib monotherapy or combination therapy for patients with advanced or recurrent biliary tract cancer (BTC)"? Return the original wording with paper, Claim, and Evidence Span referen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a04d0c77b9645b880f01e051","quotes":["Abstract Introduction The present study aims to eva... | [
"CLM:a04d0c77b9645b880f01e051",
"CLM:01f48df2009a41f6aa528ef8",
"CLM:ebddc2a22a1fa74f12cd0059"
] | [
"PMCID:PMC7903638",
"PMID:36511876"
] | [
"SPAN:f03c78e56ac6695fb2369ce5",
"SPAN:4b71444c803d3fb43699d943"
] | [
"ASC2:2bd4e1ed49581b46bf73595a"
] | [
"HYP:DCH:cc32aadefb0129fb248c5acd"
] | {"qa_id":"QA:0fcf98283bd737378a480412","qa_group_id":"QAG:bc04106ba8f94cb383e0535b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Abstract Introduction The present study aims to evaluate the effic... |
QA:14832586aae91c890c3ebd1c | QAG:1e0ecbf9bb8a2904839d67c0 | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9743639? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9743639","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9743639"
] | [] | [] | [] | {"qa_id":"QA:14832586aae91c890c3ebd1c","qa_group_id":"QAG:1e0ecbf9bb8a2904839d67c0","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9743639... |
QA:1a68e2f157cdd57d1aafa289 | QAG:583d4f7ad0e4c6caae4f8f60 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "This retrospective study aims to evaluate the efficacy of anti-PD-1 (programmed cell death protein 1) treatment and find the therapeutic prognostic biomarkers in advanced biliary tract cancer (BTC)"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:90c71eb0d04076112f4cfb4e","quotes":["This retrospective study a... | [
"CLM:90c71eb0d04076112f4cfb4e",
"CLM:01f48df2009a41f6aa528ef8",
"CLM:45c1b2ab1b095ced64b09d41",
"CLM:63b44d6d6c0c8ea054497cd3"
] | [
"PMID:33724548",
"PMCID:PMC8071846",
"PMCID:PMC9364266"
] | [
"SPAN:1187fcfc0769617d832e2b6c",
"SPAN:85735780c68d7f5e73dcb378",
"SPAN:381684665dd9bcf947dabf9b"
] | [
"ASC2:b9b962f2fe05c7fb965726bd",
"ASC2:63c8c0efeb657e988871be46"
] | [
"HYP:DCH:9110d742688ffe1506651f39",
"HYP:DCH:5b567a53bee4eca89dd1b251"
] | {"qa_id":"QA:1a68e2f157cdd57d1aafa289","qa_group_id":"QAG:583d4f7ad0e4c6caae4f8f60","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"This retrospective study aims to evaluate the efficacy of anti-PD-... |
QA:1b9e55f873eb1aa04b6b4751 | QAG:c7098a490361d1972b72671d | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8710793? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8710793","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8710793"
] | [] | [] | [] | {"qa_id":"QA:1b9e55f873eb1aa04b6b4751","qa_group_id":"QAG:c7098a490361d1972b72671d","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8710793... |
QA:2124b9ac2f8dc841d61fa939 | QAG:122809ee984e5e72ecc16ed1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Results A total of 28 patients with advanced or recurrent BTC who progressed after prior systemic therapies received apatinib monotherapy or combination therapy (with capecitabine, S-1, oxaliplatin, irinotecan or PD-1 inhibitor), including 9 cases of gallbladder cancer... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ed061c6fe7808ad7e0a77fc3","quotes":["Results A total of 28 pati... | [
"CLM:ed061c6fe7808ad7e0a77fc3",
"CLM:01f48df2009a41f6aa528ef8",
"CLM:873e9d557fed92965c06de55",
"CLM:0f0533c3f2e79bf1f7145583",
"CLM:70728c95cfe7baec5d4c7928"
] | [
"PMCID:PMC7903638",
"PMCID:PMC10412480",
"PMCID:PMC9817514"
] | [
"SPAN:053103f2cc42c3785888bfcb",
"SPAN:09a741ad26e37b2852157e88",
"SPAN:4f70d06bac1d2c31e88e94b3"
] | [
"ASC2:2826d2e20678014043c99295",
"ASC2:6a7e995400d24fdbad399536"
] | [
"HYP:DCH:4cd0696dd7938131296d8043",
"HYP:DCH:b83c1e671202b2e9b58c069b"
] | {"qa_id":"QA:2124b9ac2f8dc841d61fa939","qa_group_id":"QAG:122809ee984e5e72ecc16ed1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Results A total of 28 patients with advanced or recurrent BTC who ... |
QA:2a2deeb24fffc448640a7efc | QAG:d23a7a73f73b39cfb2d81e0e | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC11016659? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC11016659","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC11016659"
] | [] | [] | [] | {"qa_id":"QA:2a2deeb24fffc448640a7efc","qa_group_id":"QAG:d23a7a73f73b39cfb2d81e0e","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1101665... |
QA:2eacd8214aafc0ac1ce6a591 | QAG:7ae19bd2b5b236a274176083 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "High PD-L1 expression was associated with 725 therapeutic response to pembrolizumab in patients with advanced biliary tract cancer (vol 23, pg 726 12348, 2020)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance require... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d1d9816c289ca6e18b3a5d4f","quotes":["High PD-L1 expression is associated with 725\nthera... | [
"CLM:d1d9816c289ca6e18b3a5d4f",
"CLM:01f48df2009a41f6aa528ef8",
"CLM:6ee88a0deefdc3bc973515ca"
] | [
"PMID:37075781",
"PMCID:PMC6292555"
] | [
"SPAN:6f850abeed5bfb94ff84b209",
"SPAN:4773251a1dea6c624e28acfe",
"SPAN:c6ea4a5696ff4d3bec9a0811"
] | [
"ASC2:a7ca88c46d6a2d49dd27bc33"
] | [
"HYP:DCH:55a6d63e5e6123cdf97f70fd"
] | {"qa_id":"QA:2eacd8214aafc0ac1ce6a591","qa_group_id":"QAG:7ae19bd2b5b236a274176083","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"High PD-L1 expression was associated with 725 therapeutic response... |
QA:302d87f8207dd44dad13c89c | QAG:f6a8ab549aefeaef2862dd3f | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "21 157 158 We assessed whether adding the anti–PD-1 monoclonal antibody pembrolizumab to 159 gemcitabine and cisplatin improved efficacy compared with gemcitabine and cisplatin alone as 160 first-line therapy for advanced biliary tract cancer"? Return the original word... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ea02865089469afae43bcdae","quotes":["The 152\nrandomised, doubl... | [
"CLM:ea02865089469afae43bcdae",
"CLM:2638b91272c1767180e3b260",
"CLM:e5cb8533ab97862d115066fd",
"CLM:63b44d6d6c0c8ea054497cd3",
"CLM:b281aa25dbdd31101b2d8b96"
] | [
"PMID:37075781",
"PMCID:PMC9501891",
"PMCID:PMC9364266"
] | [
"SPAN:8006cfb2fa656bfef2fd59b1",
"SPAN:c70e12b415f4ef675dfc1461",
"SPAN:381684665dd9bcf947dabf9b"
] | [
"ASC2:4f377ba832b3cdc84a6a6387",
"ASC2:b632226908d61e162bb09af5"
] | [
"HYP:DCH:191b6109ef834e1d529c8ce8",
"HYP:DCH:d24800865d43f05ea1323538"
] | {"qa_id":"QA:302d87f8207dd44dad13c89c","qa_group_id":"QAG:f6a8ab549aefeaef2862dd3f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"21 157 158 We assessed whether adding the anti–PD-1 monoclonal ant... |
QA:317a9e9569799b7f1fc320fd | QAG:9b5cc7837bf59f5f81578664 | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10453268? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10453268","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10453268"
] | [] | [] | [] | {"qa_id":"QA:317a9e9569799b7f1fc320fd","qa_group_id":"QAG:9b5cc7837bf59f5f81578664","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1045326... |
QA:377c163064872a316023ebca | QAG:69f135e83794b59d8b2b219d | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8920361? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8920361","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8920361"
] | [] | [] | [] | {"qa_id":"QA:377c163064872a316023ebca","qa_group_id":"QAG:69f135e83794b59d8b2b219d","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8920361... |
QA:3f65ce12e6ad6b51dfc8f403 | QAG:05a65bd94cfbf7bd04dca33f | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "A‐F, MIR155HG expression was correlated with tumor purity and has significant positive relates with infiltrating levels of B cells, CD8 + T cells, CD4 + T cells, and dendritic cells (DCs) in cholangiocarcinoma (CHOL), head and neck squamous cell carcinoma (HNSC), kidne... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5fbeb5279bd0da052c5877bd","quotes":["A‐F, MIR155HG expression is negatively correlated with tumor purity and has ... | [
"CLM:5fbeb5279bd0da052c5877bd",
"CLM:889e439a1f5b975102ee45f3"
] | [
"PMCID:PMC6885872"
] | [
"SPAN:aa0a51e46caea5fc6000586c"
] | [] | [] | {"qa_id":"QA:3f65ce12e6ad6b51dfc8f403","qa_group_id":"QAG:05a65bd94cfbf7bd04dca33f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"A‐F, MIR155HG expression was correlated with tumor purity and has ... |
QA:459cbae2babbfdcf8823c229 | QAG:d4fa59a44861bb3f56abf513 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "High PD-L1 Expression was associated with Therapeutic Response to Pembrolizumab in Patients With Advanced Biliary Tract Cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supportin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:63b44d6d6c0c8ea054497cd3","quotes":["High PD-L1 Expression is A... | [
"CLM:63b44d6d6c0c8ea054497cd3",
"CLM:01f48df2009a41f6aa528ef8",
"CLM:b281aa25dbdd31101b2d8b96",
"CLM:90c71eb0d04076112f4cfb4e"
] | [
"PMCID:PMC9364266",
"PMID:37075781",
"PMID:33724548"
] | [
"SPAN:381684665dd9bcf947dabf9b",
"SPAN:8006cfb2fa656bfef2fd59b1",
"SPAN:1187fcfc0769617d832e2b6c"
] | [
"ASC2:b632226908d61e162bb09af5",
"ASC2:63c8c0efeb657e988871be46"
] | [
"HYP:DCH:0b6a98a1d29cfed1d74b651c",
"HYP:DCH:d7c71a7c18be8c02d87ffdcb"
] | {"qa_id":"QA:459cbae2babbfdcf8823c229","qa_group_id":"QAG:d4fa59a44861bb3f56abf513","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"High PD-L1 Expression was associated with Therapeutic Response to ... |
QA:4626569088634a5b02a6edb4 | QAG:12afb36b1dae3b0e5de6a1f8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Conclusion Immune-related RNA signature predicted the outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma, which could be tested as a biomarker for immune-chemotherapy in the future"? Return the original wording with paper, Cla... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e5cb8533ab97862d115066fd","quotes":["Conclusion Immune-related RNA signature predicts th... | [
"CLM:e5cb8533ab97862d115066fd",
"CLM:01f48df2009a41f6aa528ef8",
"CLM:0f0533c3f2e79bf1f7145583",
"CLM:b281aa25dbdd31101b2d8b96",
"CLM:ea02865089469afae43bcdae"
] | [
"PMCID:PMC9501891",
"PMCID:PMC10412480",
"PMID:37075781"
] | [
"SPAN:c70e12b415f4ef675dfc1461",
"SPAN:09a741ad26e37b2852157e88",
"SPAN:8006cfb2fa656bfef2fd59b1"
] | [
"ASC2:3c1496c475a86f697873ed7a",
"ASC2:4f377ba832b3cdc84a6a6387"
] | [
"HYP:DCH:9484d91a43ae98d895edc305"
] | {"qa_id":"QA:4626569088634a5b02a6edb4","qa_group_id":"QAG:12afb36b1dae3b0e5de6a1f8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Conclusion Immune-related RNA signature predicted the outcome of P... |
QA:4c33867a86fbca1fca4fc5ba | QAG:9cef56bc88f1342a993ad765 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Patients with programmed death‐ligand 1 (PD‐L1)‐positive tumors had improved overall survival compared with patients with PD‐L1‐negative disease"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return t... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6ee88a0deefdc3bc973515ca","quotes":["Patients with programmed death‐ligand 1 (PD‐L1)‐positive tumors had improved... | [
"CLM:6ee88a0deefdc3bc973515ca",
"CLM:2638b91272c1767180e3b260"
] | [
"PMCID:PMC6292555"
] | [
"SPAN:4773251a1dea6c624e28acfe",
"SPAN:c6ea4a5696ff4d3bec9a0811"
] | [] | [] | {"qa_id":"QA:4c33867a86fbca1fca4fc5ba","qa_group_id":"QAG:9cef56bc88f1342a993ad765","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Patients with programmed death‐ligand 1 (PD‐L1)‐positive tumors ha... |
QA:4c629bb7f59d3f92dd504ebe | QAG:0834515c0fccbb54d1161227 | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10149806? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10149806","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10149806"
] | [] | [] | [] | {"qa_id":"QA:4c629bb7f59d3f92dd504ebe","qa_group_id":"QAG:0834515c0fccbb54d1161227","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1014980... |
QA:4da6c47b850675260f068407 | QAG:810fe34e6fdfd25d3b320887 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Herein, we aims to evaluate the efficacy and safety for advanced intrahepatic cholangiocarcinoma (ICC) in a multicenter real-world study"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:93809a56356f38b7bf17bc79","quotes":["Herein, we aimed to investigate the efficacy and safety for advanced intrahe... | [
"CLM:93809a56356f38b7bf17bc79",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC10412480"
] | [
"SPAN:174e8e9d5d57c2f83749d4dc"
] | [] | [] | {"qa_id":"QA:4da6c47b850675260f068407","qa_group_id":"QAG:810fe34e6fdfd25d3b320887","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Herein, we aims to evaluate the efficacy and safety for advanced i... |
QA:4e09aec6b08d467b77731de1 | QAG:4cbc0a4e5ab2975bbccf6703 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "PD‐1 and PD‐L1 expression is upregulated in intrahepatic cholangiocarcinoma tumor tissues and was associated with both poor differentiation and stage, whereas increased CD8 + T cells in tumors was associated with better tumor differentiation"? Return the original wordi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bc30620acc8af7c9183f0f2c","quotes":["PD‐1 and PD‐L1 expression is upregulated in intrahepatic cholangiocarcinoma ... | [
"CLM:bc30620acc8af7c9183f0f2c",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC6292555"
] | [
"SPAN:4d96240157693e69cf5fbfd7"
] | [] | [] | {"qa_id":"QA:4e09aec6b08d467b77731de1","qa_group_id":"QAG:4cbc0a4e5ab2975bbccf6703","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"PD‐1 and PD‐L1 expression is upregulated in intrahepatic cholangio... |
QA:51ddff17187b19a6e9127223 | QAG:194af841b6f3236b11acba67 | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8326820? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8326820","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8326820"
] | [] | [] | [] | {"qa_id":"QA:51ddff17187b19a6e9127223","qa_group_id":"QAG:194af841b6f3236b11acba67","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8326820... |
QA:5276ada19b2f74d332bc701a | QAG:8c0f81fdca98f8bd7c560332 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Intrahepatic cholangiocarcinoma (iCCA), which represents <10% of all CCA cases and is often diagnosed at an advanced disease stage was associated with poor prognosis and limited life expectancy"? Return the original wording with paper, Claim, and Evidence Span referenc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:80ff1234c03e09441b46df41","quotes":["Intrahepatic cholangiocarcinoma (iCCA), which represents <10% of all CCA cas... | [
"CLM:80ff1234c03e09441b46df41",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC9529477"
] | [
"SPAN:fe9b03d8bf884b0767d8a643"
] | [] | [] | {"qa_id":"QA:5276ada19b2f74d332bc701a","qa_group_id":"QAG:8c0f81fdca98f8bd7c560332","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Intrahepatic cholangiocarcinoma (iCCA), which represents <10% of a... |
QA:5ef7c946cc3a6aa71824324d | QAG:b6f3c7a7e73c09e83d03bedb | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34082024? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:34082024","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:34082024"
] | [] | [] | [] | {"qa_id":"QA:5ef7c946cc3a6aa71824324d","qa_group_id":"QAG:b6f3c7a7e73c09e83d03bedb","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34082024? E... |
QA:613ee13346a595f307f5601e | QAG:a52d8055c3af3dcabc097de0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Human cholangiocarcinoma cell lines HuCCT1 and TFK1 received gemcitabine (10 μM) or oxaliplatin (3 mg/ml) for the indicated time; the cells were detached and stained with anti-PDL1-APC (BioLegend, 323124)"? Return the original wording with paper, Claim, and Evidence Sp... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:14ee7e7d0def38838313739b","quotes":["Human cholangiocarcinoma cell lines HuCCT1 and TFK1 were treated with gemcit... | [
"CLM:14ee7e7d0def38838313739b",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC9501891"
] | [
"SPAN:9641172f751cda5ae76b7c6f"
] | [] | [] | {"qa_id":"QA:613ee13346a595f307f5601e","qa_group_id":"QAG:a52d8055c3af3dcabc097de0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Human cholangiocarcinoma cell lines HuCCT1 and TFK1 received gemci... |
QA:632decd0ba8e7d2006563e78 | QAG:306f440e2100bea274988a32 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "A total of 104 patients with advanced ICC who received a PD-1 inhibitor combined with lenvatinib and Gemox chemotherapy were enrolled in this study from June 2020 to September 2022. The primary eligibility criteria were histologically confirmed intrahepatic cholangioca... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0f0533c3f2e79bf1f7145583","quotes":["A total of 104 patients wi... | [
"CLM:0f0533c3f2e79bf1f7145583",
"CLM:01f48df2009a41f6aa528ef8",
"CLM:70728c95cfe7baec5d4c7928",
"CLM:873e9d557fed92965c06de55",
"CLM:e5cb8533ab97862d115066fd",
"CLM:b281aa25dbdd31101b2d8b96"
] | [
"PMCID:PMC10412480",
"PMCID:PMC9817514",
"PMCID:PMC9501891",
"PMID:37075781"
] | [
"SPAN:09a741ad26e37b2852157e88",
"SPAN:4f70d06bac1d2c31e88e94b3",
"SPAN:c70e12b415f4ef675dfc1461",
"SPAN:8006cfb2fa656bfef2fd59b1"
] | [
"ASC2:6a7e995400d24fdbad399536",
"ASC2:27f7d3ae8599c837812b02c2",
"ASC2:3c1496c475a86f697873ed7a"
] | [
"HYP:DCH:f7a3f92dc5f8fb6c96f64c4c",
"HYP:DCH:3dde2315c2bc6299222246a7"
] | {"qa_id":"QA:632decd0ba8e7d2006563e78","qa_group_id":"QAG:306f440e2100bea274988a32","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"A total of 104 patients with advanced ICC who received a PD-1 inhi... |
QA:66475bd0e4e42f29f762b647 | QAG:896b8c45f009dee130c1d9ee | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "(2) The patient has not received systemic treatment for unresectable biliary cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence S... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0cd4a518b9857b8b887e4fac","quotes":["(2) The patient has not received systemic treatment for unresectable biliary... | [
"CLM:0cd4a518b9857b8b887e4fac",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC9817514"
] | [
"SPAN:a5b78ff8c05cf3b13477492c"
] | [] | [] | {"qa_id":"QA:66475bd0e4e42f29f762b647","qa_group_id":"QAG:896b8c45f009dee130c1d9ee","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"(2) The patient has not received systemic treatment for unresectab... |
QA:693366a645f52ce64862e6ce | QAG:f356fe5f0102a09c5b93150e | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:37331095? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:37331095","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:37331095"
] | [] | [] | [] | {"qa_id":"QA:693366a645f52ce64862e6ce","qa_group_id":"QAG:f356fe5f0102a09c5b93150e","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:37331095? E... |
QA:6be00852a53007d3c6decb65 | QAG:e8e403540ade5037f1f2cda6 | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10313915? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10313915","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10313915"
] | [] | [] | [] | {"qa_id":"QA:6be00852a53007d3c6decb65","qa_group_id":"QAG:e8e403540ade5037f1f2cda6","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1031391... |
QA:72dc58231f29999d9b1b7f23 | QAG:dc68630c2830a9dac2cb676f | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7355970? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC7355970","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC7355970"
] | [] | [] | [] | {"qa_id":"QA:72dc58231f29999d9b1b7f23","qa_group_id":"QAG:dc68630c2830a9dac2cb676f","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7355970... |
QA:737e135859abb655bc0aeca1 | QAG:7e65806daa85ee3e9f49ab55 | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6643449? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6643449","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6643449"
] | [] | [] | [] | {"qa_id":"QA:737e135859abb655bc0aeca1","qa_group_id":"QAG:7e65806daa85ee3e9f49ab55","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6643449... |
QA:74f70b6d348fe5b323f52d91 | QAG:e3f0666074c5ce08ebe1417a | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "Patients must not have received prior immunotherapy, therapy with checkpoint inhibitors, or anti-TGF-β therapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:12775d2690911f4d4f44497c","quotes":["Patients must not have received prior immunotherapy, therapy with checkpoint... | [
"CLM:12775d2690911f4d4f44497c",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC6421170"
] | [
"SPAN:8bf52bfc5b60048b88faa97f",
"SPAN:cb76f18ebe8d35e2eece6496"
] | [] | [] | {"qa_id":"QA:74f70b6d348fe5b323f52d91","qa_group_id":"QAG:e3f0666074c5ce08ebe1417a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"Patients must not have received prior immunotherapy, therapy with ... |
QA:75d7eada2cb8ba59a41adc9c | QAG:391fcd8d30134c07283bbbfc | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "PD‐1 and PD‐L1 expression is upregulated in intrahepatic cholangiocarcinoma tumor tissues and was associated with both poor differentiation and stage, whereas increased CD8 + T cells in tumors was associated with better tumor differentiation"? Return the original wordi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:04a818b687b537542b6f6718","quotes":["PD‐1 and PD‐L1 expression is upregulated in intrahepatic cholangiocarcinoma ... | [
"CLM:04a818b687b537542b6f6718",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC6292555"
] | [
"SPAN:4d96240157693e69cf5fbfd7"
] | [] | [] | {"qa_id":"QA:75d7eada2cb8ba59a41adc9c","qa_group_id":"QAG:391fcd8d30134c07283bbbfc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"PD‐1 and PD‐L1 expression is upregulated in intrahepatic cholangio... |
QA:7c5f019985945f1ddb256d32 | QAG:2a3cb071768ef2adf07bf6ec | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "The 152 randomised, double-blind, phase 3 TOPAZ-1 study of patients with advanced biliary tract cancer 153 showed that adding the PD-L1 inhibitor durvalumab to gemcitabine and cisplatin significantly 154 improved overall survival compared with gemcitabine and cisplatin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b281aa25dbdd31101b2d8b96","quotes":["The 152\nrandomised, double-blind, phase 3 TOPAZ-1 ... | [
"CLM:b281aa25dbdd31101b2d8b96",
"CLM:2638b91272c1767180e3b260",
"CLM:63b44d6d6c0c8ea054497cd3",
"CLM:70728c95cfe7baec5d4c7928",
"CLM:ea02865089469afae43bcdae"
] | [
"PMID:37075781",
"PMCID:PMC9364266",
"PMCID:PMC9817514"
] | [
"SPAN:8006cfb2fa656bfef2fd59b1",
"SPAN:381684665dd9bcf947dabf9b",
"SPAN:4f70d06bac1d2c31e88e94b3"
] | [
"ASC2:b632226908d61e162bb09af5",
"ASC2:97855f2f20ac19e0fa17b5df"
] | [
"HYP:DCH:be8cbd5945a4c84cacdbbe45"
] | {"qa_id":"QA:7c5f019985945f1ddb256d32","qa_group_id":"QAG:2a3cb071768ef2adf07bf6ec","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"The 152 randomised, double-blind, phase 3 TOPAZ-1 study of patient... |
QA:7ed2423a5b1f6b97029024d9 | QAG:7785f497213d11739fdb174f | provenance_qa | paper_evidence_availability | provenance_qa | G027 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34301762? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:34301762","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:34301762"
] | [] | [] | [] | {"qa_id":"QA:7ed2423a5b1f6b97029024d9","qa_group_id":"QAG:7785f497213d11739fdb174f","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G027","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34301762? E... |
QA:851448d1a511e1e4037cdfef | QAG:ebf9e07acfc516a3d32c3712 | provenance_qa | exact_evidence_retrieval | provenance_qa | G027 | en | train | Which exact source passage supports the statement "9 MIR155 host gene promotes glioma and GBM tumor growth, 10 , 11 and was associated with colorectal cancer pancreatic cancer, 12 laryngeal squamous cell carcinoma"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2638b91272c1767180e3b260","quotes":["9 MIR155 host gene promotes glioma and GBM tumor growth, 10 , 11 and is asso... | [
"CLM:2638b91272c1767180e3b260",
"CLM:01f48df2009a41f6aa528ef8"
] | [
"PMCID:PMC6885872"
] | [
"SPAN:cf95dec5e885194c47fe64f9"
] | [] | [] | {"qa_id":"QA:851448d1a511e1e4037cdfef","qa_group_id":"QAG:ebf9e07acfc516a3d32c3712","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G027","question":"Which exact source passage supports the statement \"9 MIR155 host gene promotes glioma and GBM tumor growth, 10 , 11 a... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.